Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Completed
National Cancer Institute (NCI)
N/A
2010-11-01
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer
receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work
better by making tumor cells more sensitive to the drug
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Completed
University of Washington
N/A
2010-11-01
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer
receiving aromatase inhibitor (AI) therapy. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Vorinostat may also help AI therapy work
better by making tumor cells more sensitive to the drug
Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer
Completed
Assistance Publique - Hôpitaux de Paris
N/A
2012-06-01
Compare the response rate after 6 months of hormone treatment (or a major change in hormone
treatment) in metastatic breast cancer, according to the uptake of FES in metastatic lesions
taking-up FDG on PET/CT at baseline. Hypothesis: best response rate will be observed in
patients with all metastases taking up FES prior to treatment.
A significant number of all invasive breast cancers are hormone sensitive and may be
candidates for treatment with hormonal therapy.
This project will assess the ability and usefulness of imaging hormone-receptor status in
breast cancer with positron emission tomography (PET) and 6α-[18F]fluoro-17β-estradiol (FES),
an estrogen analogue in patients who are scheduled to be treated with hormonal therapy given
in combination with a selective allosteric inhibitor of AKT protein kinase (MK2206) .
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
